Introduction
============

Acute respiratory distress syndrome (ARDS) is a common cause of respiratory failure in the intensive care unit. Patients with ARDS exhibit an intense inflammatory reaction centered in the lung parenchyma, resulting in alveolar flooding and collapse, in reduced lung compliance, in increased work of breathing, and in severe impairments in gas exchange \[[@B1]-[@B4]\]. Patients with ARDS have an inhospital mortality rate ranging from 34% to 60% \[[@B5]\]. Treatment of patients with ARDS is largely supportive, and includes mechanical ventilation with low tidal volumes \[[@B6]\], positive end expiratory pressure to open collapsed alveoli \[[@B7]\], supplemental oxygen, and supportive care of other organ system failures. Given the high mortality rate of patients with ARDS, other therapies are clearly needed.

Administration of exogenous pulmonary surfactant is an adjunctive therapy that may help adult patients with ARDS. Pulmonary surfactant is produced by type II alveolar cells and is composed of two major fractions: phospholipids (90%) and surfactant-specific proteins (10%). Surfactant decreases alveolar surface tension, thereby preventing alveolar collapse and allowing efficient gas exchange at low transpulmonary pressures. Furthermore, surfactant has important roles in host immune defense, through both specific and nonspecific mechanisms \[[@B8]\].

Patients with ARDS show injury to the alveolar epithelial barrier with consequent surfactant dysfunction. Indeed, surfactant recovered from bronchoalveolar lavage fluid from ARDS patients has alterations of the phospholipid and fatty acid profile, has decreased levels of surfactant-specific proteins, and has impaired surface-tension-lowering properties. Causes of this impairment include the inhibition of surfactant function by protein-rich edema fluid, by surfactant lipid peroxidation, and by surfactant protein degradation \[[@B1],[@B9]\]. Given these abnormalities, administration of exogenous pulmonary surfactant has been considered a possible treatment option in adult patients with ARDS \[[@B8]\].

The purpose of this study was to perform a systematic review and meta-analysis of exogenous surfactant administration to assess whether this therapy, as currently administered, may be useful in adult patients with ARDS.

Materials and methods
=====================

Study identification
--------------------

We performed a computerized search to identify articles that compared treatment with exogenous pulmonary surfactant against the usual therapy for patients diagnosed with ARDS. For our analysis, we only included studies that were randomized controlled clinical trials, that compared the use of exogenous pulmonary surfactant to an appropriate control group (defined as patients receiving standard therapy with or without a placebo), that evaluated mortality and/or pulmonary physiological parameters, and that used objective documentation of ARDS using accepted criteria at the time of the individual study publication. Abstracts, case reports, editorials, nonhuman studies, and nonEnglish studies were excluded.

We performed a computerized literature search of MEDLINE (1966--December 2005), EMBASE (1980--December 2005), Cochrane Database of Systematic Reviews (1996--December 2005), Cochrane controlled trials register (1996--December 2005), and the Database of Abstracts and Reviews of Effects (1994--December 2005) to identify clinical studies and systematic reviews. We conducted the search for human studies using the following combination of exploded medical subject headings and text words: (\'adult respiratory distress syndrome\' or \'acute respiratory distress syndrome\' or \'ARDS\') and (\'pulmonary surfactant\' or \'lung surfactant\') and (\'adult\'). The reference lists of all articles selected were then hand-searched for additional citations missed in the search.

Study selection
---------------

Two authors (WJD, NTA) independently reviewed the abstracts of the references identified to determine suitability for inclusion. Studies that could potentially be included were obtained and reviewed in detail. Examiners were not blinded to authors, to institutions, or to journal name.

Data extraction
---------------

Information about relevant outcome measures was extracted for each study. Our primary outcome measure was mortality 28--30 days after randomization. Secondary outcome measures included a change in oxygenation (specifically the change in the ratio between the partial pressure of oxygen and the fraction of inspired oxygen (PaO~2~:FiO~2~ratio)), the number of ventilation-free days, and the mean duration of ventilation. Furthermore, the following data were extracted: method of randomization; inclusion and exclusion criteria; details of surfactant administration, including type of surfactant, dose, duration, and delivery method; nature of control treatment; mean age or age range; gender ratio; ARDS scoring system; etiologies of ARDS; and ventilation strategy.

Methodologic quality was assessed using the Jadad scoring system, which consists of items describing randomization (0--2 points), blinding (0--2 points), and dropouts and withdrawals (0--1 points) in reporting of a randomized controlled trial \[[@B10]\]. A higher score indicates improved reporting. One author (WJD) extracted the data, which were reviewed by the two other authors (NTA, DD). If disagreement occurred, all three authors met to establish consensus. If relevant data were missing or unclear from a particular trial, we attempted to contact the primary author of that study.

Statistical analysis
--------------------

Meta-analysis was performed using the inverse variance method. Statistical heterogeneity was evaluated using the Q statistic with *P*\< 0.1. The primary outcome was summarized as the odds ratio (OR) with the 95% confidence interval (CI). A fixed-effect model was used unless there was significant heterogeneity, in which case we applied a random effects model. We examined the influence of the method of delivery and the type of surfactant on all trials using predetermined sensitivity analyses. All statistical analyses were performed using Stata Version 8.0 (Statacorp LP, College Station, Texas, USA).

Ethics
------

Ethics approval and patient consent were not applicable for this meta-analysis.

Results
=======

Search Results
--------------

We initially identified 251 articles. Of these, we excluded 238 because titles or abstracts were not relevant. Thirteen studies were retrieved for detailed review \[[@B11]-[@B23]\]. Four studies were added from a hand search of articles and clinical trials \[[@B24]-[@B27]\]. Twelve studies were not eligible for analysis (Table [1](#T1){ref-type="table"}): seven were in abstract form only \[[@B21]-[@B27]\], four had no control group \[[@B11]-[@B13],[@B27]\], and one was a crossover trial \[[@B15]\]. Five studies met our inclusion criteria (Table [2](#T2){ref-type="table"}) \[[@B16]-[@B20]\]. The study by Spragg and colleagues \[[@B20]\] included results from both a North American trial and a European--South African trial. For the purposes of our analysis, therefore, the data from the two trials in this manuscript were assessed independently, resulting in the final analysis of data from six randomized controlled trials \[[@B16]-[@B20]\].

Study characteristics
---------------------

The studies were published from November 1994 to August 2004 (Table [2](#T2){ref-type="table"}). All were multicenter trials. The number of patients in each trial ranged from 39 to 725. Different doses of surfactant were used in three trials \[[@B16],[@B18],[@B19]\].

In an effort to analyze the most comparable data, the surfactant group in the study by Weg and colleagues \[[@B16]\] with the closest dosing to the surfactant group in the study by Anzueto and colleagues \[[@B17]\] was chosen for analysis. This resulted in the exclusion of 17 patients.

A similar issue was found in the four trials using surfactant containing surface protein. Specifically, in the trial by Spragg and colleagues \[[@B19]\] the surfactant group chosen for analysis was the group who were given the same dose of surfactant as the two other trials \[[@B20]\] using the same type of surfactant (recombinant surface protein C). This resulted in the exclusion of 12 patients. In the trial by Gregory and colleagues \[[@B18]\] the group that received the higher dose of surfactant was used for analysis. As a result, 24 patients were excluded from the analysis.

A total of 1,270 patients were analyzed in these six trials: 381 patients were given surfactant containing no surfactant protein (two trials) \[[@B16],[@B17]\]; 239 patients were given surfactant containing recombinant surfactant protein C (three trials) \[[@B19],[@B20]\]; and 19 patients were given bovine surfactant containing both surfactant proteins B and C (one trial) \[[@B18]\].

All studies included ARDS resulting from sepsis. Two studies only included patients with sepsis-related ARDS, both pulmonary and nonpulmonary \[[@B16],[@B17]\]. The remaining studies included patients with other direct lung injury (aspiration) and indirect lung injury (trauma or surgery, transfusions, pancreatitis, burns, and toxic injury).

Primary outcome (mortality at 28 or 30 days)
--------------------------------------------

Overall, treatment with exogenous pulmonary surfactant was not associated with reduced mortality compared with the control group (Figure [1](#F1){ref-type="fig"} and Table [3](#T3){ref-type="table"}). That is, compared with the control group, the OR for mortality after treatment with surfactant was 0.97 (95% CI 0.73, 1.30). Subgroup analysis revealed no difference between the aerosolized and intratracheal instillation methods: OR 0.99 (95% CI 0.74, 1.32) and 0.87 (95% CI 0.48, 1.58), respectively (Table [3](#T3){ref-type="table"}).

Furthermore, the OR for mortality was similar regardless of whether the surfactant contained surface protein or not. That is, the pooled OR for mortality was 1.08 (95% CI 0.72, 1.64) for the two trials using surfactant without surface protein \[[@B16],[@B17]\], and was 0.87 (95% CI 0.48, 1.58) for the four trials using surfactant containing surface protein B and/or protein C \[[@B18]-[@B20]\] (Table [3](#T3){ref-type="table"}).

Secondary outcomes
------------------

Due to the constraints of the published data, the mean difference in change in the PaO~2~:FiO~2~ratio between the surfactant and control groups could only be assessed at the 24-hour mark following treatment administration. Three studies had sufficient information to allow pooling of the PaO~2~:FiO~2~data \[[@B19],[@B20]\]. These three trials studied a total of 488 patients (251 patients in the surfactant arm and 237 patients in the control arm). A fixed-effect model was used because the Q test for heterogeneity was not significant (*P*= 0.11). There was a trend for the surfactant group to have improved oxygenation compared with the controls. This did not achieve statistical significance, however (pooled mean change 13.18 mmHg, standard error 8.23 mmHg; 95% CI -2.95, 29.32) (Figure [2](#F2){ref-type="fig"}).

The number of ventilation-free days and the mean duration of ventilation could not undergo pooled analysis due to a lack of sufficient data.

Discussion
==========

Adult patients with ARDS exhibit a reduction in the amount and function of surface-active material recovered by bronchoalveolar lavage. In addition, the phospholipid, fatty acid, and apoprotein profiles of pulmonary surfactant are altered \[[@B1]\]. It would therefore seem sensible that exogenous pulmonary surfactant would be a useful therapy in the treatment of ARDS. Our meta-analysis of six randomized controlled trials, however, demonstrated little utility of the therapy \[[@B16]-[@B20]\]. There was no overall improvement in mortality (OR 0.97; 95% CI 0.73, 1.30). Furthermore, subgroup analysis of preparations with surfactant proteins in addition to phospholipids did not demonstrate improved outcomes (OR 0.87; 95% CI 0.48, 1.58). In three of the studies we were able to assess the impact of surfactant on oxygenation (for instance the PaO~2~:FiO~2~ratio 24 hours following surfactant administration). Although there was a trend to improved oxygenation, this did not reach statistical significance (mean change 13.18 mmHg, standard error 8.23 mmHg; 95% CI -2.95, 29.32).

Our search for all published randomized controlled trials was thorough. Each study was assessed for quality and was chosen only if they were similar with respect to study participants and outcome measure. Mortality was chosen as the primary outcome given its importance in clinical practice. Unlike the most recent published meta-analysis \[[@B28]\], we attempted to assess oxygenation (PaO~2~:FiO~2~ratio), the number of ventilation-free days, and the mean duration of ventilation. Unfortunately, there were limited data available for analysis of the change in oxygenation and insufficient data for assessment of ventilation characteristics. It is possible that we may have missed some published and unpublished articles.

The quality of the studies varied in our meta-analysis. Using the Jadad scoring system \[[@B10]\], four of the studies were of high quality (Jadad score 4 or 5) \[[@B16],[@B17],[@B20]\] but two studies were not (Jadad score 2) \[[@B18],[@B19]\] (Table [4](#T4){ref-type="table"}). Of the latter two studies, one was a phase I/II prospective, randomized trial while the other was open-labeled. Notably these two studies had the lowest OR for mortality, and their exclusion, which would favor the null hypothesis, would not have changed our results significantly.

A limitation of our analysis is the many differences among the various studies. First, different types of surfactant were used. Two of the studies used synthetic surfactant (Exosurf) containing no surfactant protein \[[@B16],[@B17]\]. These studies have been criticized given the emerging data on the importance of surfactant proteins in the proper functioning of surfactant \[[@B29],[@B30]\]. It has been shown that surfactant-associated protein concentrations are decreased in bronchoalveolar lavage samples obtained from patients with ARDS compared with samples from control subjects \[[@B3]\]. Four surfactant proteins have been previously identified (SP-A, SP-B, SP-C, and SP-D). SP-B and SP-C are hydrophobic proteins that enhance the lowering of surface tension \[[@B8]\]. In the three studies using protein-based surfactant, two were recombinant preparations incorporating SP-C \[[@B19],[@B20]\] while the other was a bovine extract with both SP-B and SP-C \[[@B18]\]. SP-A and SP-D are hydrophilic proteins whose role appears to center around host defense \[[@B8]\]. None of the trials in our analysis, however, used surfactant containing SP-A or SP-D. It is possible that the presence of these proteins could increase the effectiveness of therapy.

Second, the different delivery methods used may have resulted in varying concentrations of surfactant reaching the damaged alveoli and altering the effectiveness of therapy. It has been shown that the relative rate of pulmonary deposition of surfactant is 4--5% using the aerosolization route \[[@B17],[@B29],[@B30]\]. In the article by Anzueto and colleagues \[[@B17]\] this would correspond to delivery of less than 5 mg/kg/day phospholipid, while other investigations have suggested that administration of 300 mg/kg/day may be required \[[@B30]\]. The ability of intratracheal administration, the method used by most of the studies in this meta-analysis, to effectively deliver of surfactant to the alveoli is unclear. Delivery of surfactant using the bronchoscopic route has been shown to be efficacious and safe, with initial studies showing improved oxygenation and a trend toward improved mortality \[[@B11]-[@B15]\]. None of the trials using this method, however, met the inclusion criteria for our analysis. Nevertheless, bronchoscopic administration may be a potential promising path of future investigation.

Third, there were a variety of other differences between the studies including ventilation strategies and the time to surfactant administration. In this meta-analysis, three studies utilized the low tidal volume approach \[[@B19],[@B20]\] while one trial used traditional tidal volumes \[[@B18]\]. Two trials did not specify the ventilation strategy used \[[@B16],[@B17]\]. Most studies required administration of surfactant within 48 hours of the diagnosis of ARDS. One study allowed administration up to 72 hours after ARDS was diagnosed \[[@B20]\]. The timing of administration is an important issue as the response to early therapy versus delayed therapy may be significant \[[@B3]\].

Finally, the populations that were studied included patients with a wide variety of predisposing causes for ARDS. Patients with ARDS associated with indirect causes, for example sepsis, trauma, or pancreatitis, have a greater number of potentially fatal comorbidities than do patients with ARDS from direct causes such as aspiration or pneumonia \[[@B20]\]. Surfactant is unlikely to prevent nonpulmonary causes of death, and thus may only be effective in the subset of ARDS patients with direct lung injury. In a recent study of pediatric patients with acute lung injury, treatment with surfactant significantly improved oxygenation and survival in the subgroup of patients with direct acute lung injury, while having little effect on patients with indirect acute lung injury \[[@B31]\]. To date, studies focusing on the adult population with direct acute lung injury have not been reported.

Our results confirm and extend those of Adhikari and colleagues \[[@B28]\], who recently published a meta-analysis of a variety pharmacologic agents (for instance prostaglandin E, *N*-acetylcysteine, high-dose steroids, pulmonary surfactant, pentoxifylline) used in the treatment of ARDS and acute lung injury. Their review had significant differences compared with ours, however. First, five of the nine studies included in their review were abstracts, several of which did not include a placebo group. Second, they were only able to assess early mortality and did not include the change in the PaO~2~:FiO~2~ratio. Finally, they did not perform subgroup analyses. Despite these methodologic differences, their results were consistent with ours in that exogenous pulmonary surfactant was found to have no significant effect on mortality (relative risk 0.93; 95% CI 0.77, 1.12).

Conclusion
==========

We found in our meta-analysis that exogenous surfactant may improve oxygenation but did not improve mortality. Given the abnormalities of surfactant function found in patients with ARDS, the lack of effectiveness of exogenous surfactant is somewhat surprising. One potential explanation is that patients with ARDS usually die of multi-organ system failure from their underlying disease process (for example sepsis) rather than from respiratory failure *per se*. As such, treatment of the pulmonary abnormalities may not affect mortality substantially. Evaluation of surfactant treatment of patients with direct lung injury may clarify this issue. Another potential explanation is that the proper \'surfactant recipe\' has not yet been found. That is, there may be a dose, formulation, and delivery strategy of surfactant that could be effective in patients in ARDS, potentially when combined with other therapies such as lung protective ventilation \[[@B6]\], high-frequency ventilation \[[@B32]\], prone positioning \[[@B33]\], or extracorporeal membrane oxygenation \[[@B34]\]. Future studies may eventually discover such an approach, but exogenous surfactant cannot currently be considered an effective adjunctive therapy in ARDS.

Key messages
============

• Exogenous pulmonary surfactant may improve oxygenation in patients with ARDS.

• Exogenous pulmonary surfactant cannot currently be considered an effective adjunctive therapy in patients with ARDS.
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ARDS = acute respiratory distress syndrome; CI = confidence interval; FiO~2~= fraction of inspired oxygen; OR = odds ratio; PaO~2~= partial pressure of oxygen in arterial blood.
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![Forest plot of mortality. This Forest plot represents the odds ratio (OR) (95% confidence interval) for 28-day to 30-day mortality in patients treated with surfactant compared with controls. OR \< 1 indicates that treatment with surfactant was associated with a reduction in mortality compared with the control group, while OR \> 1 indicates an increase in mortality with surfactant therapy. Areas of boxes are proportional to the respective study weight within the corresponding pooled analysis (see also weight values on the right). Eur-SA, European--South African trial; NA, North American trial.](cc4851-1){#F1}

![Forest plot of the PaO~2~:FiO~2~ratio. This Forest plot represents the mean difference in the change in the PaO~2~:FiO~2~ratio (mmHg) of surfactant compared with controls. A positive value (i.e. right of 0) indicates that treatment with surfactant resulted in improved oxygenation at 24 hours compared with controls. Areas of boxes are proportional to the respective study weight within the corresponding pooled analysis (see also weight values on the right). Eur-SA, European--South African trial; NA, North American trial.](cc4851-2){#F2}

###### 

Characteristics of the trials not eligible for meta-analysis

  Reference                                Number of patients   Exclusion criteria                                                     Delivery method   Type of surfactant                           Other remarks
  ---------------------------------------- -------------------- ---------------------------------------------------------------------- ----------------- -------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reines and colleagues, 1992 \[27\]       49                   Abstract only                                                          Aerosolized       Exosurf (synthetic, no surfactant protein)   Published as an abstract. Placebo-controlled. Trend for improvement in the PaO~2~:FiO~2~ratio and mortality
  MacIntyre and colleagues, 1994 \[26\]    10                   Abstract only. No control group. No data on oxygenation or mortality   Aerosolized       Exosurf (synthetic, no surfactant protein)   Published as an abstract. Only 4.5% of aerosolized radiolabeled surfactant reached the lungs
  Spragg and colleagues, 1994 \[15\]       6                    Crossover trial                                                        Bronchoscopic     Porcine surfactant                           Trend for improved oxygenation. Findings of reduced inhibition of surfactant function in bronchoalveolar lavage fluid after surfactant replacement
  Walmrath and colleagues, 1996 \[13\]     10                   No control group                                                       Bronchoscopic     Alveofact (natural bovine surfactant)        Trend for improvement in oxygenation (PaO~2~:FiO~2~ratio)
  Pallua and colleagues, 1998 \[12\]       4                    No control group                                                       Bronchoscopic     Alveofact (natural bovine surfactant)        Improved oxygenation (PaO~2~:FiO~2~ratio)
  Wiswell and colleagues, 1999 \[11\]      12                   No control group                                                       Bronchoscopic     Surfaxin (synthetic surfactant)              Surfactant administration was safe. FiO~2~and positive end-expiratory pressure decreased after treatment initiation
  Walmrath and colleagues, 2000 \[25\]     41                   Abstract only                                                          Intratracheal     Venticute (rSP-C-based surfactant)           Published as an abstract. Randomized. Trend for improvement in PaO~2~:FiO~2~ratio, number of ventilator-free days and successful weaning at 28 days in patients receiving surfactant
  Kesecioglu and colleagues, 2001 \[22\]   36                   Abstract only                                                          Intratracheal     Porcine surfactant                           Published as an abstract. Randomized. Surfactant administration was safe. PaO~2~:FiO~2~ratio and survival were improved in surfactant group
  Spragg and colleagues, 2001 \[24\]       40                   Abstract only                                                          Intratracheal     Venticute (rSP-C-based surfactant)           Published as an abstract. Randomized. Surfactant treatment may reduce acute pulmonary inflammation
  Walmrath and colleagues, 2002 \[14\]     27                   No control group                                                       Bronchoscopic     Alveofact (natural bovine surfactant)        Surfactant administration was safe. Improved PaO~2~:FiO~2~ratio
  Spragg and colleagues, 2002 \[23\]       448                  Abstract only                                                          Intratracheal     Venticute (rSP-C-based surfactant)           Published as an abstract. Randomized. Improved PaO~2~:FiO~2~ratio. No mortality benefit
  Gregory and colleagues, 2003 \[21\]      22                   Abstract only. No control group                                        Bronchoscopic     Surfaxin (synthetic surfactant)              Published as an abstract. Procedure found to be safe and tolerable

rSP-C, recombinant surfactant protein C.

###### 

Characteristics of the trials eligible for meta-analysis

  Article (Jadad score)                           Design                              Number of patients                                           Delivery method   Type of surfactant                                        Surfactant dosing (total)                                                                                                     Treatment duration                 Number of deaths   Ventilation-free days^a^                Duration of ventilation^b^                                                          
  ----------------------------------------------- ----------------------------------- ------------------------------------------------------------ ----------------- --------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ---------------------------------- ------------------ --------------------------------------- ---------------------------- ----------------------------------------- ------------ --------------------------------------------------
  Weg and colleagues, 1994 \[16\] (score 5)       Multicenter: USA, Canada            51 (control = 17, group 1 = 17, group 2 = 17)                Aerosolized       Exosurf (synthetic, no surfactant protein)                13.5 mg DPPC/ml (group 1, 21.9 mg DPPC/kg/day; Group 2, 43.5 mg DPPC/kg/day)                                                  Maximum 120 hours for all groups   8                  Group 1 = 7, group 2 = 6                NA                           NA                                        NA           NA
  Anzueto and colleagues, 1996 \[17\] (score 5)   Multicenter: USA, Spain, France     725 (control = 361, surfactant = 364)                        Aerosolized       Exosurf (synthetic, no surfactant protein)                13.5 mg DPPC/ml (112 mg DPPC/kg/day)                                                                                          Maximum 5 days                     143                145                                     NA                           NA                                        16.4 (0.9)   16.0 (1.0)
  Gregory and colleagues, 1997 \[18\] (score 2)   Multicenter: USA                    59 (control = 16, group 1 = 8, group 2 = 16, group 3 = 19)   Intratracheal     Survanta bovine lung extract (containing SP-B and SP-C)   Group 1, 50 mg/kg LBW (maximum 8 doses); group 2, 100 mg/kg LBW (maximum 4 doses); group 3, 100 mg/kg LBW (maximum 8 doses)   Maximum 96 hours for all groups    7                  Group 1 = 4, group 2 = 3, group 3 = 3   NA                           NA                                        10           Group 1 = 15^c^, group 2 = 7^c^, group 3 = 10^c^
  Spragg and colleagues, 2003 \[19\] (score 2)    Multicenter: USA, Canada            40 (control= 13, group 1 = 15, group 2 = 12)                 Intratracheal     Venticute (rSP-C-based surfactant)                        Group 1, 1 mg/kg LBW (maximum 4 doses); group 2, 0.5 ml/kg LBW (maximum 4 doses)                                              24 hours for all groups            5                  Group 1 = 3, group 2 = 4                6 (0--15)                    Group 1= 5 (0--18), group 2 = 4 (0--12)   NA           NA
  Spragg and colleagues, 2004 \[20\] (score 4)    Multicenter: Europe, South Africa   227 (control = 109, surfactant = 118)                        Intratracheal     rSP-C-based surfactant                                    1 mg/kg LBW (maximum 4 doses)                                                                                                 24 hours                           43                 46                                      0 (0--20)                    0 (0--19)                                 NA           NA
  Spragg and colleagues, 2004 \[20\] (score 4)    Multicenter: USA, Canada            221 (control = 115, surfactant = 106)                        Intratracheal     rSP-C-based surfactant                                    1 mg/kg LBW (maximum 4 doses)                                                                                                 24 hours                           29                 34                                      6 (0--21)                    3.5 (0--21)                               NA           NA

DPPC, dipalmitoylphosphatidylcholine; LBW, lean body weight; rSP-C, recombinant surfactant protein C; NA, not available.

^a^Values presented as median (25th--75th percentile).

^b^Values presented as mean (± standard deviation).

^c^Values presented as median.

###### 

Principal outcome measures in patients according to type of surfactant and method of delivery

  Outcome                                           Number of trials   Number of patients   Heterogeneity   *P*value   Fixed-effects model \[odds ratio (95% CI)\]   Random-effects model \[odds ratio (95% CI)\]                       
  ------------------------------------------------- ------------------ -------------------- --------------- ---------- --------------------------------------------- ---------------------------------------------- ------------------- -------------------
  Overall mortality                                 6                  631                  639             6.00       0.17                                          0.31                                           0.99 (0.79, 1.25)   0.97 (0.73, 1.30)
  Method of delivery                                                                                                                                                                                                                    
   Aerosolized \[16,17\]                            2                  378                  381             0.48       0                                             0.49                                           0.99 (0.74, 1.32)   \-
   Intratracheal \[18-20\]                          4                  253                  258             5.52       0.46                                          0.14                                           1.00 (0.69, 1.46)   0.87 (0.48, 1.58)
  Type of surfactant                                                                                                                                                                                                                    
   Synthetic \[16,17\] (no surfactant protein)      2                  378                  381             2.21       0.55                                          0.14                                           1.09 (0.74, 1.60)   1.08 (0.72, 1.64)
   Recombinant \[19,20\] (SP-C)                     3                  237                  239             0.36       0                                             0.84                                           0.99 (0.74, 1.32)   \-
   Recombinant + bovine \[18-20\] (SP-B and SP-C)   4                  253                  258             5.52       0.46                                          0.14                                           1.00 (0.69, 1.46)   0.87 (0.48, 1.58)

^a^In the studies by Weg and colleagues \[16\], Gregory and colleagues \[18\], and Spragg and colleagues \[19\], those patients who received a comparable surfactant dose (the higher dose) were used for the pooled analysis.

###### 

Jadad scoring items and allocation concealment of each study eligible for meta-analysis

                                                            Weg and colleagues, 1994 \[16\]                                   Anzueto and colleagues, 1996 \[17\]                                             Gregory and colleagues, 1997 \[18\]   Spragg and colleagues, 2003 \[19\]                                      Spragg and colleagues, 2004 \[20\]
  --------------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------- ----------------------------------------------------------------------- ------------------------------------
  Jadad scoring items                                                                                                                                                                                                                                                                                                       
  Was the study randomized?                                 Yes                                                               Yes                                                                             Yes                                   Yes                                                                     Yes
  Was the randomization method described and appropriate?   Yes                                                               Yes                                                                             No                                    Yes                                                                     No
  Was the study described as double-blind?                  Yes                                                               Yes                                                                             No                                    No                                                                      Yes
  Was the method of blinding described and appropriate      Yes                                                               Yes                                                                             No                                    No                                                                      Yes
  Was there a description of withdrawals and dropouts?      Yes                                                               Yes                                                                             Yes                                   No                                                                      Yes
  Inappropriate method of randomization?                    No                                                                No                                                                              No                                    No                                                                      No
  Inappropriate method of blinding?                         No                                                                No                                                                              No                                    No                                                                      No
  Allocation concealment                                    Central office provided randomization assignment to study sites   Independent central facility provided randomization assignment to study sites   Not clearly stated                    Centralized facility provided randomization assignment to study sites   Not clearly stated
